Collegium Pharmaceutical, Inc. (COLL) News
Filter COLL News Items
COLL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
COLL News Highlights
- COLL's 30 day story count now stands at 33.
- Over the past 28 days, the trend for COLL's stories per day has been choppy and unclear. It has oscillated between 1 and 12.
- The most mentioned tickers in articles about COLL are BDSI, SGEN and AYTU.
Latest COLL News From Around the Web
Below are the latest news stories about Collegium Pharmaceutical Inc that investors may wish to consider to help them evaluate COLL as an investment opportunity.
Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni On Q4 2021 Results - Earnings Call TranscriptCollegium Pharmaceutical, Inc. (COLL) Q4 2021 Earnings Conference Call February 24, 2022, 04:30 PM ET Company Participants Alex Dasalla - Head of Investor Relations & Corporate Communications Joe Ciaffoni - President, CEO & Director Colleen Tupper - CFO Scott Dreyer - Chief Commercial Officer Conference Call Participants David Amsellem -... |
Collegium Reports Fourth Quarter and Full-Year 2021 Financial Results– BDSI Acquisition Expected to Close Late Q1 2022 – – 2022 Revenue Guidance of $315-$330 Million, Growth Driven by Xtampza ER – – Full-Year Net Income of $71.5 Million and Full-Year Adjusted EBITDA of $118.3 million – – Cash Balance of $186.4 Million – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the fourth quarter and full-year 2021 and provided a |
Allogene (ALLO) Beats on Q4 Earnings, Resumes Clinical StudiesAllogene (ALLO) beats earnings estimates for the fourth quarter. However, the stock declines in after-market trading. All clinical studies have been resumed following the removal of clinical hold last month. |
Esperion (ESPR) Q4 Earnings Beat, Product Sales Rise 49%Esperion Therapeutics (ESPR) reports solid fourth-quarter results, beating estimates for earnings and sales. Stock surges. |
Halozyme (HALO) Q4 Earnings Top, Royalties Drive RevenuesHalozyme (HALO) fourth-quarter earnings and sales beat estimates. The company expects royalty revenues to grow by approximately 50% in 2022. |
Is a Beat Likely for Perrigo (PRGO) This Earnings Season?Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter. |
10 Best Pharmaceutical Stocks to Buy in 2022In this article, we discuss the 10 best pharmaceutical stocks to buy in 2022. If you want to skip our detailed analysis of the pharmaceutical industry and these stocks, go directly to 5 Best Pharmaceutical Stocks to Buy in 2022. In a post-COVID world, pharmaceutical and biotech companies will be expected to make larger strides […] |
Analysts Predict An Collegium Pharmaceutical Inc. (NASDAQ: COLL) Spike?Collegium Pharmaceutical Inc. (NASDAQ:COLL) shares, rose in value on Friday, 02/18/22, with the stock price down by -1.09% to the previous days close as strong demand from buyers drove the stock to $21.75. Actively observing the price movement in the last trading, the stock closed the session at $21.99, falling within a range of $21.21 Analysts Predict An Collegium Pharmaceutical Inc. (NASDAQ: COLL) Spike? Read More » |
Ironwood (IRWD) Q4 Earnings Miss, Linzess Volume GrowsIronwood (IRWD) witnesses flat year-over-year sales growth. Its fourth-quarter earnings miss estimates. The company maintains revenue guidance for 2022. Stock declines. |
Has Aytu BioPharma Inc. (AYTU) Outpaced Other Medical Stocks This Year?Here is how Aytu BioPharma Inc. (AYTU) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year. |